Biological activity of plant raw materials subject to the counter drug addiction act
Keywords:
ethnobotany, plants, hallucinogens of natural originAbstract
Psychoactive plants have been a part of human life for ages. Used by priests and healers for ritual and medical purposes in the past, at present, psychoactive plants pose a social problem leading to addiction and death of many people. In Poland a July 29, 2005 act and alterations of thereof define the principles and the course of action in counteracting drug addiction. The act concerns substances obtained in the process of chemical synthesis, a dozen or so plants, including opium poppy and marihuana, opium poppy and marihuana products, and compounds isolated from plants. Plant substances included in an alteration to a March 20, 2009 act had not been known in Poland before. Problems with the availability of those substances occurred in Poland in 2008, when those substances, called then “designer drugs” or “legal highs,” were considered to be legal. Little is known about the biological effects caused by the plants included in the act. There is a lack of information about the mechanisms of actions of effectual compounds and about compounds responsible for psychoactive influence. A lack of awareness of health consequences stemming from taking those substances for a longer time poses a threat to young people willing to experiment with new narcotics. This essay will describe 16 psychoactive plants included in the act: Argyreia nervosa, Banisteriopsis caapi, Calea zacatechichi, Catha edulis, Echinopsis pachanoi, Kava kava, Leonotis leonurus, Mimosa tenuiflora, Mitragyna speciosa, Nymphaea caerulea, Peganum harmala, Psychotria viridis, Rivea corymbosa, Salvia divinorum, Tabernanthe iboga, Trichocereus peruvianus.
Downloads
References
Stan problemu narkotykowego w Europie. Sprawozdanie roczne 2010. Europejskie Centrum Monitorowania Narkotyków i Narkomanii. Urząd Publikacji Unii Europejskiej. Luksemburg, 2010.
Ustawa o przeciwdziałaniu narkomanii. Dz. U. 2005 nr 179 poz. 1485 z późniejszymi zmianami.
Brzeziński T.: Historia medycyny. Wydawnictwo Lekarskie PZWL, Warszawa 1995.
Szukalski B.: Narkotyki. Kompendium wiedzy o środkach uzależniających. Inastytut Psychiatrii i Neurologii, Warszawa 2005.
Seńczuk W.: Toksykologia współczesna. Wydawnictwo Lekarskie PZWL, Warszawa 2005.
Farmakopea Polska Wydanie VIII, Polskie Towarzystwo Farmaceutyczne, Warszawa 2008.
Lamer-Zarawska E., Kowal-Gierczak B., Niedworok J.: Fitoterapia i leki roślinne, Wydawnictwo Lekarskie PZWL, Warszawa 2007.
Baker P.B., Gough T.A., Johncock S.I.M., Taylor B.J., Wyles L.T.:Variation in the THC content in illicitly imported Cannabis products – Part II. United Office on Drugs and Crime, 1982.
Klinke H.B., Müller I.B., Steffenrud S., Dahl-Srensen R.: Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby Woodrose. Forensic Sci Int. 2010; 197, e1-e5.
Tofern B., Kaloga M., Wutte L., Hartmann T., Eich E.: Occurrence of loline alkaloids in Argyreia mollis (Convolvulaceae). Phytochemistry. 1999; 51, 1177-1180.
Wang Y.H., Samoylenko V., Tekwani B.L., Khan I.A., Miller L.S., Chaurasiya N.D.: Composition, standardization and chemical profiling of Banisteriopsis caapi, a plant for the treatment of neurodegenerative disorders relevant to Parkinson's disease, J Ethnopharmacol. 2010; 128, 662–671.
Schwarz M.J., Haughton P.J., Rose S., Jenner P., Lees A.D.: Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonizm. Pharmacol Biochem Behav. 2003; 75, 627–633.
Samoylenko V., Rahman Md. M., Tekwani B.L., Tripathi L.M., Wang Y.H., Khan S.I.: Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson's disease. J Ethnopharmacol. 2010; 127, 357–367.
Köhler I., Jenet-Siems K., Siems K., Hernández M.A., Ibarra R., Berendsohn W.: In vitro Antiplasmodial Investigation of Medicinal Plants fom El Salvador. Z Naturforsch. 2002; 57 c, 277-281.
Vengas-Flores H., Segura-Cobos D., Vazquez-Cruz B., Antiinflamatory Activity of the Aqueous Extract of Calea zacatechichi, Proc West Pharmacol Soc. 2002; 45, 110-111..
Wu H., Fronczek F., Burandt C., Zjawiony J.: Antileishmanial Germacranolides from Calea zacatechichi. Planta Med. 2011; 77, 749-753.
Mayagoitia L., Díaz J.L., Contreras C.: Psychopharmologic analysis of an alleged oneirogenic plant: Calea zacatechichi; J Ethnopharmacol. 1986; 18, 229-243.
Laussman T., Meier-Giebing S., Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography. Forensic Sci Int. 2010; 195, 160–164.
Toennes S.W., Harder S., Schramm M., Niess C., Kauert G.F.: Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. Br J Clin Pharmacol. 2003; 56, 125-130.
Murray Ch.D.R., Le Roux C.W., Emmanuel A.V., Halket J.M., Przyborowska A.M., Kamm M.A.: The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion. Appetite. 2008; 51, 747–750.
Al-Akwa A.A., Shaher M., Al-Akwa S., Aleryani S.L.: Free radicals are present in human serum of Catha edulis Forsk (Khat) abusers. J Ethnopharmacol. 2009; 125, 471–473.
Bilia A.R., Scalise L., Bergonzi M.C., Vincieri F.F.: Analysis of kavalactones from Piper methysticum (kava-kava). J Chromatogr B. 2004; 812, 203–214.
Xuan T.D., Fukuta M., Wei A.Ch., Elzaawely A.A., Khanh T.D., Tawata S.: Efficacy of extracting solvents to chemical components of kava (Piper methysticum) roots. J Nat Med. 2008; 62, 188–194.
Dharmaratne H.R.W., Nanayakkara N.P.D., Khan I.A.: Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochemistry. 2002; 59, 429–433.
Whittaker P., Clarke J.J., San R.H.C., Betz J.M., Seifried H.E., de Jager L.S.: Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. Food Chem Toxicol. 2008; 46, 168–174.
Yamazaki Y., Hashida H., Arita A., Hamaguchi K., Shimura F.: High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem Toxicol. 2008; 46, 3732–3738.
Lüde S., Török M., Dieterle S., Jäggi R., Büter K.B., Krähenbühl S.: Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine. 2008; 15, 120–131.
Teschke R., Genthner A., Wolff A.: Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava – herbs mixtures. J Ethnopharmacol. 2009; 123, 378-384.
Naidoo D., Maharaj V., Crouch N.R., Ngwane A.: New labdane-type diterpenoids from Leonotis leonurus support circumscription of Lamiaceae s.l.. Biochem Syst Ecol. 2011; 39, 216-21.
McKenzie J.M., Greenb I.R., Mugabo P.: Leonurun, a novel labdane diterpenoid from Leonotis leonurus. S Afr J Chem. 2006; 59, 114-116.
Jimoh F.O., Adedapo A.A., Afolayan A.J.: Comparison of the nutritional value and biological activities of the acetone, methanol and water extracts of the leaves of Solanum nigrum and Leonotis leonorus. Food Chem Toxicol. 2010; 48, 964-971.
Bienvenu E., Amabeoku G.J., Eagles P.K., Scott G., Springfield E.P.: Anticonvulsant activity of aqueous extract of Leonotis leonurus. Phytomedicine. 2002; 9, 217-223.
Maphosa V., Masika P.J., Bizimenyera E.S., Eloff J.N.: In-vitro anthelminthic activity of crude aqueous extracts of Aloe ferox, Leonotis leonurus and Elephantorrhiza elephantia against Haemonchus contortus. Trop Anim Health Prod. 2010; 42, 301-307.
Stafford G.I., Jäger A.K., van Staden J.: Effect of storage on the chemical composition and biological activity of several popular South African medicinal plants. J Ethnopharmacol. 2005; 97, 107-115.
Zippel J., Deters A., Hensel A.: Arabinogalatcans from Mimosa tenuiflora (Willd.) Poiret bark as active principles for wound-healing properties: Specific enhancement of dermal fibroblast activity and minor influence on HaCaT keratinocytes. J Ethnopharmacol. 2009; 124, 391-396.
Rivera-Arce E., Chavez-Soto M.A., Herrera-Arellano A., Arzate S., Agüero J., Feria-Romero I.A.: Therapeutic effectiveness of a Mimosa tenuiflora cortex extract in venous leg ulceration treatment. J Ethnopharmacol. 2007; 109, 523-528.
de Souza R.S.O., de Albuquergue U.P., Monteiro J.M., de Amorim E.L.C.: Jurema-Preta (mimosa tenuiflora [Willd.] Poir.): a review of its traditional use, phytochemistry and pharmacology. Braz Arch Biol Technol. 2008; 51, 937-947.
Philipp A.A., Meyer M.R., Wissenbach D.K., Weber A.A., Zoernlein S.W., Zweipfenning P.G.M.: Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Anal Bioanal Chem. 2011; 400, 127–135.
Kikura-Hanajiri R., Kawamura M., Maruyama T., Kitajima M., Takayama H., Goda Y.: Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and othe alkaloids in the psychotropic plant „kratom” (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol. 2009; 27, 67-74.
Babu K.M., McCurdy C.R., Boyer E.W.: Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol. 2008; 46, 146-152.
Matsumoto K., Horie S., Ishikawa H., Takayama H., Aimi N., Ponglux D.: Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004; 74, 2143–2155.
Chan K.B., Pakiam C., Rahim R.A.: Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. Bull Narc. 2005; 57, 249-256.
Agnihotri V.K., ElSohly H.N., Khan S.I., Smillie T.J., Khan I.A., Walker L.A.: Antioxidant constituents of Nymphaea caerulea flowers. Phytochemistry. 2008; 69, 2061–2066.
Berlant S.R.: The entheomycological origin of Egyptian crowns and the esoteric underpinnings of Egyptian religion. J Ethnopharmacol. 2005; 102, 275-288.
Kartal M., Altun M.L., Kurucu S.: HPLC method for the analysis of harmol, harmalol, harmine and harmaline in the seeds of Peganum harmala L. J Pharm Biomed Anal. 2003; 31, 263-269.
Herraiz T., González D., Ancín-Azpilicueta C., Arán V.J., Guillén H.: -Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol. 2010, 48, 839–845.
Astulla A., Zaima K., Matsuno Y., Hirasava Y., Ekasari W., Widaywaruyanti A.: Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. J Nat Med. 2008; 62, 470–472.
Farouk L., Laroubi A., Aboufatima R., Benharref A., Chait A.: Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: Possible mechanisms involved. J Ethnopharmacol. 2008; 115, 449-454.
Agedilova M.T., Turmukhambetov A.Zh., Kazantsev A.V., Shul’ts E.E., Shakirov M.M., Adekenov S.M.: Isolation and chemical transformations of vasicinone. Chem Nat Compounds. 2004; 40, 273-275.
Derakhshanfar A., Oloumi M.M., Mirzaie M.: Study on the effect of Peganum harmala extract on experimental skin wound healing in rat: pathological and biomechanical findings. Comp Clin Pathol. 2010; 19, 169–172.
Nenaah G.: Antibacterial and antifungal activities of (beta)-carboline alkaloids of Peganum harmala (L) seeds and their combination effects. Fitoterapia. 2010; 81, 779-782.
Frison G., Favretto D., Zancanaro F., Fazzin G., Ferrara S.D.: A case of -carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci Int. 2008; 179, 37–43.
Singh A.B., Chaturvedi J.P., Narender T., Srivastava A.K.: Preliminary studies on the hypoglycemic effect of Peganum harmala L. Seeds ethanol extract on normal and streptozotocin induced diabetic rats. Indian J Clin Biochem. 2008; 23 (4), 391-393.
Yalcin D., Bayraktar O.: Inhibition of catechol-O-methyltransferase (COMT) by some plant-derived alkaloids and phenolics. J Mol Catalysis B: Enzymatic. 2010; 64, 162-166.
McKenna D.J., Towers G.H.N., Abbott F.S.: Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and -carboline constituents of ayahausca. J Ethnopharmacol. 1984; 10, 195-223.
Rivier L., Lindgren J.: Ayahausca, the South American hallucinogenic drink: Ethnobotanical and chemical investigations. Economic Botany. 1972; 29, 101-129.
Shulgin A.T.: Profiles of psychodelic drugs: DMT. J Psychodelic Drugs. 1976; 8, 167-168.
McKenna D.J., Callaway J.C., Grob C.S.: The scientific investigation of Ayahusca. A review of past and current research. The Heffter review of psychedelic research, vol.1, 1998.
Tupper K. W.: The globalization of ayahuasca: Harm reduction or benefit maximization ? Int J Drug Policy. 2008; 19, 297-303.
Cakic V., Potkonyak J., Marshall A.: Dimethyltryptamine (DMT): Subjective effects and patterns of use among Australian recreation users. Drug Alcohol Depend. 2010; 111, 30-37.
Appel J., Kim-Appel D.: The rise of a new psychoactive agent: Salvia divinorum. Int J Ment Health Addiction. 2007; 5, 248-253.
Mendelson J.E., Coyle J.R., Lopez J.C., Baggott M.J., Flower K., Everhart E.T.: Lack of effect of sublingual salvinorin A, a naturally occuring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacol. 2011; 214, 933-939.
Teksin Z.S., Lee I.J., Nemieboka N.N., Othman A.A., Upreti V.V., Hassan H.E.: Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm. 2009; 72, 471-477.
Walentiny D.M., Vann R.E., Warner J.A., King L.S., Seltzman H.H., Navarro H.A.: Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacol. 2010; 210, 275-284.
Ma Z., Deng G., Dai R., Xu W., Liu-Chen L.Y., Lee D.Y.W.: Thermal degradation products derived from the smoke. Tetrahedron Lett. 2010; 51, 5480-5482.
Lee D.Y.W., Yang L., Xu W., Deng G., Guo L., Liu-Chen L.Y.: Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A. Bioorg Med Chem Lett. 2010; 20, 5749-5752.
Fontana G., Savona G., Rodriguez B., Dersch Ch.M., Rothman R.B., Prisinzano T.E.: Synthetic studiem of neoclerodane diterpenoids from Salvia splendens and evaluation of opioid receptor affinity. Tetrahedron. 2008; 64, 10041-10048.
Carroll F.I., Harris L.S., Aceto M.D.: Effects of JDTic, a selective -opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur J Pharmacol. 2005; 524, 89-94.
Schmidt M.M., Sharma A., Schifano F., Feinmann Ch.: ‘‘Legal highs’’ on the net—Evaluation of UK-based Websites, products and product information. Forensic Sci Int. 2011; 206, 92–97.
Miller B.L., Griffin O.H., Gibson Ch.L., Khey D.N.: Trippin’ on Sally D: Exploring predictors of Salvia divinorum experimentation. J Crim Just. 2009; 37, 396–403.
Baggott M.J., Erowid E., Erowid F., Galloway G.P., Mendelson J.: Use patterns and self-reported effects of Salvia divinorum: An internet-based survey. Drug Alcohol Depend. 2010; 111, 250–256.
Lange J.E., Daniel J., Homer K., Reed M.B., Clapp J.D.: Salvia divinorum: Effects and use among YouTube users. Drug Alcohol Depend. 2010; 108, 138–140.
Alper K.R., Lotsof H.S., Kaplan C.D.: The ibogaine medical subculture. J Ethnopharmacol. 2008; 115, 9-24.
Chéze M., Lenoan A., Deveaux M, Pépin G.: Determination of ibogaine and noribogaine in biological fluids and hair by LC–MS/MS after Tabernanthe iboga abuse: Iboga alkaloids distribution in a drowning death case. Forensic Sci Int. 2008; 176, 58–66.
Alper K.R.: Ibogaine: a review. Chapter 1. The Alkaloids. 2001; 56, 1-38.
Alburges M.E., Ramos B.P., Bush L., Hanson G.R.: Responses of the extrapyramidal and limbic substance P systems to ibogaine and cocaine treatment. Eur J Pharmacol. 2000; 390, 119–126.
Bhargava N.H., Cao Y.J., Zhao G.M.: Effects of ibogaine and noribogaine on the antinociceptive action of -, - and -opioid receptor agonists in mice. Brain Res. 1997; 752, 234-238.
Kontrimavičt V., Breton H., Mathieu O., Mathieu-Daudé J.C., Bressolle F.M.M.: Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood Application to a poisoning involving Tabernanthe iboga root. J Chromatogr B. 2006; 843, 131-141.
Rezvani A.H., Overstreet D.H., Perfumi M., Massi M.: Plant derivatives in the treatment of alcohol dependency. Pharmacol Biochem Behav. 2003; 75, 593-606.
Maas U., Strubelt S.: Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses. 2006; 67, 960-964.
Ogunbodede O., McCombs D., Trout K., Daley P., Terry M.: New mescaline concentrations from 14 taxa/cultivars of Echinopsis spp. (Cactaceae) (“San Pedro”) and their relevance to shamanic practice. J Ethnopharmacol. 2010; 131, 356-362.
Halpern J.H., Sewell R.A.: Hallucinogenic botanicals of America: A growing need for focused drug education and research. Life Sci. 2005; 78, 519 – 526.
Pálenícék T., Balíková M., Bubeníková-Valešá V., Horáček J.: Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacol. 2008; 196, 51–62.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Medical Journal of the Rzeszow University and the National Medicines Institute, Warsaw
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
